Profile
Sector:
HealthcareCountry:
CanadaIPO:
29 March 1994Website:
http://www.bauschhealth.comNext earnings report:
21 February 2025Last dividends:
10 November 2010Next dividends:
N/APrice
after hours | 111 min agoDividend
Analysts recommendations
Institutional Ownership
BHC Latest News
The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BHC's third-quarter adjusted earnings and revenues beat estimates. The increase in revenue guidance is positive.
Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure patients receive timely, optimal care1 LAVAL, QC / ACCESSWIRE / October 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today released Liver Health Trends Report in Action, the latest Liver Health Annual Trends Report dedicated to sparking actionable change to improve liver disease management and outcomes for patients. Healthcare provider (HCP) survey participants called for holistic, multi-disciplinary treatment approaches, consistent use of non-invasive screening tools (e.g.
Bausch Health NYSE: BHC stock has been on a wild ride recently, with a dramatic surge in value over the last month. The catalyst for this surge is a wave of rumors suggesting that Bausch + Lomb NYSE: BLCO, Bausch Health's spinoff eye care business, is considering a buyout.
BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push out maturities on some of its debt.
Tom Yeung here with your Sunday Digest. During the early 1990s real estate crisis, the Marriott Corp. hotel chain found itself in trouble.
Bausch Health's debt burden and potential bankruptcy risks are mitigated by the likely sale of Bausch + Lomb, which could fetch a premium price. Bausch + Lomb's stable business and the recent acquisition of XIIDRA position it well for a sale, potentially valuing it at $10bn-$18bn. Hedge fund managers Carl Icahn and Paulson & Co. are major stakeholders at Bausch Health, reducing bankruptcy risk and supporting a strategic sale of Bausch + Lomb.
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward earnings, with a current ratio of 1.66, providing flexibility despite recent unprofitability. Risks include potential failure of takeover, economic downturns, inflation, and majority ownership by BHC, which could affect independent operations.
What type of business is Bausch Health Companies?
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
What sector is Bausch Health Companies in?
Bausch Health Companies is in the Healthcare sector
What industry is Bausch Health Companies in?
Bausch Health Companies is in the Drug Manufacturers - Specialty & Generic industry
What country is Bausch Health Companies from?
Bausch Health Companies is headquartered in Canada
When did Bausch Health Companies go public?
Bausch Health Companies initial public offering (IPO) was on 29 March 1994
What is Bausch Health Companies website?
https://www.bauschhealth.com
Is Bausch Health Companies in the S&P 500?
No, Bausch Health Companies is not included in the S&P 500 index
Is Bausch Health Companies in the NASDAQ 100?
No, Bausch Health Companies is not included in the NASDAQ 100 index
Is Bausch Health Companies in the Dow Jones?
No, Bausch Health Companies is not included in the Dow Jones index
When was Bausch Health Companies the previous earnings report?
No data
When does Bausch Health Companies earnings report?
The next expected earnings date for Bausch Health Companies is 21 February 2025